{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-036821","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.157073+00:00","generated_at":"2026-05-15T08:25:28.715053+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial","bullets":["Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.","Confirmed partial response in PPP2R1A-mutated endometrial cancer patient at 220 mg; target lesion reduction 59.5%, CA-125 drop from 362 to 40.2 U/mL.","Two partial responses in endometrial cancer with PPP2R1A mutations; five stable diseases including HPV+ HNSCC, colorectal, and endometrial cancers.","Cash runway extended into Q1 2028; dose escalation to 300 mg QD planned in Q2 2026.","Oversubscribed offering; Oppenheimer & Co. and Maxim Group acted as placement agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-036821","json":"https://secwatch.observer/filing/0001104659-26-036821.json","markdown":"https://secwatch.observer/filing/0001104659-26-036821.md","text":"https://secwatch.observer/filing/0001104659-26-036821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/0001104659-26-036821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/tm2610566d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:25:28.715053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f78cbccf1dbbf50709c1c3c1b62131f55065332d","claim":"Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Gross proceeds of approximately $30 million (effective 2026-03-30).","evidence_excerpt":"On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.683 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/0001104659-26-036821-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"Gross proceeds of approximately $30 million"},{"label":"Effective","value":"2026-03-30"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}